Patents and licences
In December, Panion signed the important license agreement with CombiGene, giving Panion access to experimental study data, patents, and developments with the exclusive right to exploit and market the epilepsy product in dogs and cats within territories of the USA, Europe and Switzerland.
The payment consists of a three million Swedish kronor sum, which will be remitted when Panion has secured financing for its operations, plus royalties on future sales.
Our plan is to use all the robust research performed and planned by CombiGene to move faster into the clinical studies in dogs, and we are actively reaching out to potential clinical investigators.
CombiGene made the choice of final drug candidate in June 2016; we follow their work closely and congratulate them on the progress.